A Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose Escalation Trial to Explore the Potential Antidyskinetic Properties of Safinamide in Patients With Parkinson's Disease Suffering From Levodopa Induced Dyskinesias.

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose Escalation Trial to Explore the Potential Antidyskinetic Properties of Safinamide in Patients With Parkinson's Disease Suffering From Levodopa Induced Dyskinesias.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2015

At a glance

  • Drugs Safinamide (Primary)
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms Safinamide-LID
  • Sponsors Newron Sweden AB
  • Most Recent Events

    • 03 Mar 2012 This trial is recruiting in France and Austria as reported by European Clinical Trials Database record.
    • 25 Jan 2012 Actual patient number (26) and additional locations (Austria, Canada) added as reported by ClinicalTrials.gov.
    • 25 Jan 2012 Actual end date (January 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top